PubmedID,Title,Publication Date,Non-academic Author(s),Company Affiliation(s),Corresponding Author Email
37219993,"CRISPR Therapeutics, Vertex Complete Rolling Biologics License Applications for Exa-Cel in Sickle Cell Disease, Beta Thalassemia.",2023-May-N/A,Alex Philippidis,"Mary Ann Liebert, Inc., Publishers, New Rochelle, New York, USA.",N/A
36873375,Immunogenicity of CRISPR therapeutics-Critical considerations for clinical translation.,2023-N/A-N/A,Karen S Anderson,"Center for Personalized Diagnostics, Biodesign Institute, Arizona State University, Tempe, AZ, United States.",N/A
29150002,Gene Editing and CRISPR Therapeutics: Strategies Taught by Cell and Gene Therapy.,2017-N/A-N/A,Juan C Ramirez,"VIVEbioTECH, San Sebasti√°n, Spain. Electronic address: jcramirez@vivebiotech.com.",N/A
